Safety of engineered allergen-specific immunotherapy vaccines

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 5, 2012, Pages 555-563

  Focke Tejkl, Margarete ^a   Valenta, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

allergen; allergy; engineered vaccines; immunotherapy; safety

Indexed keywords

ALLERGEN; BESTATIN; BUPIVACAINE; CALCITRIOL; DNA VACCINE; EPITOPE; FOOD ALLERGEN; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 13; LIPOPLEX; LIPOSOME; PLASMID DNA; POLLEN EXTRACT; PROTEIN VP1; VACCINE;

ALKYLATION; AMINO ACID SEQUENCE; ANAPHYLAXIS; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; BIOENGINEERING; CELLULAR IMMUNITY; CHEMICAL MODIFICATION; CYTOKINE RESPONSE; DENATURATION; DENDRITIC CELL; DERMATOPHAGOIDES; DESENSITIZATION; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; GRASS POLLEN; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; LOEFFLER PNEUMONIA; NONHUMAN; PEANUT ALLERGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; RECOMBINANT DNA TECHNOLOGY; REVIEW; T LYMPHOCYTE; TH1 CELL;

ALLERGENS; ANIMALS; CATS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; GENETIC ENGINEERING; HUMANS; HYPERSENSITIVITY, IMMEDIATE; TREATMENT OUTCOME; VACCINES, DNA;

EID: 84865976131     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328357ca53     Document Type: Review

References (66)

1. Kay AB. Allergy and Allergic Diseases. Oxford: Blackwell Science; 2008, 2nd ed.
2. Floistrup H, Swartz J, Bergstrom A, et al. Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol 2006; 117:59-66.
3. Noon L. Prophylactic inoculation against hayfever. Lancet 1911; 1:1572-1573.
4. Linhart B, Valenta R. Vaccines for allergy. Curr Opin Immunol 2012; 24:354-360.
5. Cooke RA, Barnard JH, Hebald S, Stull A. Serological evidence of immunity with coexisting sensitization in a type of human allergy. J Exp Med 1935; 62:733-750.
6. Valenta R, Ferreira F, Focke-Tejkl M, et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28:211-241.
7. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-562.
8. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grasspollen immunotherapy. N Engl J Med 1999; 341:468-475.
9. Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PATstudy). J Allergy Clin Immunol 2002; 109:251-256.
10. Bernstein DI, Wanner M, Borish L, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113:1129-1136.
11. Larché M. T cell epitope-based allergy vaccines. Curr Top Microbiol Immunol 2011; 352:107-119.
12. Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine 2012; 30:4328-4335.
13. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002; 2:446-453.
14. Focke M, Swoboda I, Marth K, et al. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010; 40:385-397.
15. Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011; 127:89-97.
16. Marsh DG, Lichtenstein LM, Campbell DH. Studies on 'allergoids' prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 1970; 18:705-722.
17. Riechelmann H, Schmutzhard J, van der Werf JF, et al. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy 2010; 24:e104-e109.
18. Hernández N, Ibero M, Ridao M, et al. Safety of specific immunotherapy using a depigmented and polymerised extract of dermatophagoides pteronyssinus in children under five years of age. Allergol Immunopathol (Madr) 2011; 39: 267-270.
19. Gallego MT, Iraola V, Himly M, et al. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response. Int Arch Allergy Immunol 2010; 153:61-69.
20. Pfaar O, Klimek L, Sager A, et al. Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma. Am J Rhinol Allergy 2010; 24:220-225.
21. Pfaar O, Robinson DS, Sager A, et al. Immunotherapy with depigmentedpolymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy 2011; 65:1614-1621.
22. Höiby AS, Strand V, Robinson DS, et al. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2010; 40:1062-1070.
23. Brehler R, Klimek L, Pfaar O, et al. Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts. Allergy Asthma Proc 2010; 31:e31-e38.
24. Pfaar O, Urry Z, Robinson DS, et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 2012; 67:272-279.
25. Kahlert H, Suck R, Weber B, et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 2008; 145:193-206.
26. Rak S. Clinical results with a hypoallergenic recombinant birch pollen allergen derivative [abstract]. Presented at XXVIII EAACI congress; 6-10 June 2009; Warsaw, Poland.
27. Toda M, Reese G, Gadermaier G, et al. Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen. J Allergy Clin Immunol 2011; 128:1022-1030.
28. Ferrari E, Breda D, Longhi R, et al. In search of a vaccine for mouse allergy: significant reduction of Mus m 1 allergenicity by structureguided single-point mutations. Int Arch Allergy Immunol 2012; 157:226-237.
29. Gadermaier G, Jahn-Schmid B, Vogel L, et al. Targeting the cysteinestabilized fold of Art v 1 for immunotherapy of Artemisia pollen allergy. Mol Immunol 2010; 47:1292-1298.
30. Vrtala S, Fohr M, Campana R, et al. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine 2011; 29:2140-2148.
31. Saarne T, Neimert-Andersson T, Grönlund H, et al. Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy. Allergy 2011; 66:255-263.
32. Linhart B, Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol 2004; 134:324-331.
33. Bussières L, Bordas-Le Floch V, Bulder I, et al. Recombinant fusion proteins assembling Der p 1 and Der p 2 allergens from Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2010; 153:141-151.
34. Nilsson OB, Adedoyin J, Rhyner C, et al. In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity. PLoS One 2011; 6:e24558.
35. Valenta R, Vrtala S, Focke-Tejkl M, et al. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy. Biol Chem 1999; 380:815-824.
36. Focke M, Mahler V, Ball T, et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001; 15:2042-2044.
37. Paul WE, Katz DH, Goidl EA, et al. Carrier function in antihapten immune responses. II. Specific properties of carrier cells capable of enhancing antihapten antibody responses. J Exp Med 1970; 132:283-299.
38. Focke M, Linhart B, Hartl A, et al. Nonanaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 2004; 34:1525-1533.
39. Twaroch TE, Focke M, Civaj V, et al. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol 2011; 128:178-184.
40. Chen KW, Focke-Tejkl M, Blatt K, et al. Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients: Experimental Allergy and Immunology. Allergy 2012; 67:609-621.
41. Twaroch TE, Focke M, Fleischmann K, et al. Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy. Clin Exp Allergy (in press).
42. Edlmayr J, Niespodziana K, Focke-Tejkl M, et al. Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases. Curr Top Microbiol Immunol 2011; 352:121-140.
43. Edlmayr J, Niespodziana K, Linhart B, et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009; 182:6298-6306.
44. Niespodziana K, Focke-Tejkl M, Linhart B, et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011; 127:1562-1570.
45. Rendi-Wagner P, Shouval D, Genton B, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non and low responders to conventional vaccine. Vaccine 2006; 24:2781-2789.
46. Edlmayr J, Niespodziana K, Popow-Kraupp T, et al. Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. Eur Respir J 2011; 37:44-52.
47. Wang X, Yang Q, Wang P, et al. Derp2-mutant gene vaccine inhibits airway inflammation and up-regulates Toll-like receptor 9 in an allergic asthmatic mouse model. Asian Pac J Allergy Immunol 2010; 28:287-293.
48. Pulsawat P, Piboonpocanun S, Sirivichayakul S, et al. Production and immunogenicity of hypoallergenic codon-optimized DNA vaccine encoding mature Der p 1 allergen. J Investig Allergol Clin Immunol 2010; 20:582-590.
49. Huang CF, Chu CH, Wu CC, et al. Induction of specific Th1responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Cyn d 1. Int Arch Allergy Immunol 2012; 158:142-150.
50. Weiss R, Scheiblhofer S, Roesler E, et al. J. Prophylactic mRNA vaccination against allergy. Curr Opin Allergy Clin Immunol 2010; 10:567-574.
51. Rancitelli P, Hofmann A, Burks AW. Vaccine approaches for food allergy. Curr Top Microbiol Immunol 2011; 352:55-69.
52. Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011; 127:654-660.
53. Takaiwa F. Seed-based oral vaccines as allergen-specific immunotherapies. Hum Vaccin 2011; 7:357-366.
54. Suzuki K, Yang L, Takaiwa F. Transgenic rice accumulating modified cedar pollen allergen Cry j 2 derivatives. J Biosci Bioeng 2012; 113:249-251.
55. Suzuki K, Kaminuma O, Yang L, et al. Prevention of allergic asthma by vaccination with transgenic rice seed expressing mite allergen: induction of allergen-specific oral tolerance without bystander suppression. Plant Biotechnol J 2011; 9:982-990.
56. Hiroi T, Kaminuma O, Takaiwa F. Vaccination with transgenic rice seed expressing mite allergen: a new option for asthma sufferers? Expert Rev Vaccines 2011; 10:1249-1251.
57. Yang L, Hirose S, Suzuki K, et al. Expression of hypoallergenic Der f 2 derivatives with altered intramolecular disulphide bonds induces the formation of novel ER-derived protein bodies in transgenic rice seeds. J Exp Bot 2012; 63:2947-2959.
58. Bordas-Le Floch V, Bussières L, et al. Expression and characterization of natural-like recombinant Der p 2 for sublingual immunotherapy. Int Arch Allergy Immunol 2012; 158:157-167.
59. Dioszeghy V, Mondoulet L, Dhelft V, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol 2011; 186:5629-5637.
60. Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012; 129:128-135.
61. Mondoulet L, Dioszeghy V, Vanoirbeek JA, et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol 2011; 154:299-309.
62. Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012; 129:1290-1296.
63. Creticos PS, Schroeder JT, Hamilton RG, et al. Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:1445-1455.
64. Kaburaki Y, Fujimura T, Kurata K, et al. Induction of Th1 immune responses to Japanese cedar pollen allergen (Cry j 1) in mice immunized with Cry j 1 conjugated with CpG oligodeoxynucleotide. Comp Immunol Microbiol Infect Dis 2011; 34:157-161.
65. Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009; 183:5458-5467.
66. Grundström J, Neimert-Andersson T, Kemi C, et al. Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergenspecific immunotherapy in a mouse model for cat allergy. Int Arch Allergy Immunol 2012; 157:136-146.